Last reviewed · How we verify
NCT05962944: Remote ROSE
Remote Rapid Onsite Evaluation (ROSE) for Head and Neck Fine Needle Aspirations (FNA)
trial testing Olympus Cellsens software in Head and Neck Neoplasms in 25 participants. Completed in 24 July 2023.
15 June 2023
Quick facts
| Lead sponsor | Royal Cornwall Hospitals Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 25 October 2022 |
| Primary completion | 15 June 2023 |
| Estimated completion | 24 July 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Olympus Cellsens software
Conditions studied
- Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
Sponsor
Royal Cornwall Hospitals Trust
Who can join
Adults 18 to 19, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rapid On-Site Evaluation (ROSE) of cytology FNA samples performed by a Pathologist or Biomedical Scientist is a real time morphological assessment of the sample in the clinical setting with the aim of acquiring all the diagnostic material in one appointment resulting in reduction in costs, improved patient care and reduced referral to treatment time. It is not practical or possible for the ROSE team to be present in every location where an FNA is performed. Telecytology (TC) or remote ROSE is a digital form of ROSE which allows a biomedical scientist or pathologist working in a remote laboratory to review the cytology slides in real time, using microscope images fed from the location where the FNA procedure is being performed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05962944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Neoplasms
Currently open trials in the same condition.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
- NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
- NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting
Other Royal Cornwall Hospitals Trust trials
Trials by the same sponsor.
- NCT07009431 — MHLDA Nursing Associates Focus Group · completed
- NCT06849284 — To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting · recruiting
- NCT05182710 — Simulation-based Stress Inoculation Training Study for UK Medical Professionals · NA · unknown
- NCT04821466 — VR for Symptom Control and Wellbeing · NA · completed
- NCT04297306 — Virtual Reality Exercise Gaming in Patients Awaiting Bariatric Surgery · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05962944 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Cornwall Hospitals Trust
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing